GAMMA Investing’s Generate Biomedicines GENB Stock Holding History

GAMMA Investing’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$706	Buy	+47	New	+$723	﹤0.01%	4163

Other funds holding GENB

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.31B AUM 25.55% 1-Year Est. Return

Dynamic Advisor Solutions Phoenix, Arizona $3.52B AUM 15.33% 1-Year Est. Return

Magnus Financial Group New York $1.5B AUM 16.47% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Pictet Bank & Trust Nassau, Bahamas $85.5M AUM 18.48% 1-Year Est. Return

Albion Financial Group Salt Lake City, Utah $1.77B AUM 14.95% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

GAMMA Investing's GENB Position: Q3 2026 in Review

GAMMA Investing opened a new position in Generate Biomedicines (GENB) in Q3 2026: 47 shares worth $706. The stake represents ﹤0.01% of the portfolio and ranks #4163 among its holdings.

12 funds tracked by Wall St. Rank hold GENB as of Q3 2026.

GAMMA Investing held 47 shares of Generate Biomedicines worth $706 as of Q3 2026.
Generate Biomedicines was a new GAMMA Investing position in Q3 2026.
Generate Biomedicines made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4163 holding.
12 funds tracked by Wall St. Rank held Generate Biomedicines as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.